ROIV
Roivant Sciences Ltd.
NASDAQ · Healthcare · Biotechnology · GB
$39.77
−0.53%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 268.10x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 6.79x
- Price / sales
- 3813.97x
- Price / cash flow
- -35.49x
Enterprise value
- Enterprise value
- $25.7B
- EV / sales
- 3409.78x
- EV / EBITDA
- -91.29x
- EV / EBIT
- -18.80x
- Market cap
- $28.7B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026